OBJECT: Twenty-nine nonimmunocompromised @entity1 with primary central nervous system (CNS) @entity706 were treated with high-dose @entity1499 ( @entity1500 ) therapy followed by irradiation. The authors investigated the correlation of infusion schedules with @entity1500 penetration into cerebrospinal fluid (CSF), @entity5 response, and survival to develop a regimen that would lead to better clinical results. METHODS: In this study, 100 mg/kg @entity1500 was administered on either a rapid (3-hour) or regular (6-hour) infusion schedule for two or three cycles. Of 28 assessable @entity1 , a complete or partial response was achieved in 15 (93.8%) of 16 who received rapid and in seven (58.3%) of 12 who received regular infusion therapy (p = 0.034). Rapid infusion significantly increased levels of @entity1500 in the CSF (p < 0.001) and resulted in significant @entity5 volume reduction (p < 0.001). The mean @entity5 volume after the first, second, and third cycle of rapid infusion therapy was reduced to 34%, 14%, and 9%, respectively, of the initial volume, whereas the corresponding values were 54%, 42%, and 37% for regular infusion. The reduction between the second and third cycle was small and not significant for either schedule. Despite the longer median survival time in @entity1 who underwent rapid @entity1500 infusion and irradiation (> 60 compared with 20 months), the difference in survival was not significant (p = 0.147) because of the small number of @entity1 enrolled. The median survival time was 39.3 months for all assessable @entity1 who received high-dose @entity1500 and radiation therapy, and the median relapse-free survival time was 35.2 months. CONCLUSIONS: Rapid infusion enhanced both @entity1500 penetration into the CSF and @entity5 response and may improve @entity1 survival. Administration of three or more cycles of therapy should be carefully weighed in terms of cytoreductive benefits.

Rapid infusion of high-dose @entity1499 resulting in enhanced penetration into cerebrospinal fluid and intensified XXXX response in primary central nervous system lymphomas.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity5 :: (MESH:D009369,Disease) :: ['tumor']
